Profile data is unavailable for this security.
About the company
XIAMEN AMOYTOP BIOTECH CO., LTD is a China-based company mainly engaged in the biopharmaceutical business, including the research, development, manufacture and sales of recombinant proteins and their long-acting modified drugs. The Company's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The Company distributes its products within domestic market and to overseas markets.
- Revenue in CNY (TTM)2.23bn
- Net income in CNY600.08m
- Incorporated1996
- Employees1.96k
- LocationXiamen Amoytop Biotech Co LtdNo.330 Wengjiao RoadHaicang Xinyang Industry ZoneXIAMEN 361028ChinaCHN
- Phone+86 5 926889118
- Fax+86 5 926889130
- Websitehttp://www.amoytop.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinocelltech Group Ltd | 2.17bn | -168.81m | 19.66bn | 2.33k | -- | -- | -- | 9.06 | -0.3791 | -0.3791 | 4.88 | -1.16 | 0.761 | 0.3743 | 6.86 | 930,592.90 | -5.93 | -40.17 | -15.48 | -74.63 | 96.35 | 95.42 | -7.79 | -108.20 | 0.4649 | 3.33 | 1.23 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Chongqing Taiji Industry Group Co Ltd | 15.40bn | 834.00m | 19.86bn | 12.59k | 23.81 | 5.13 | -- | 1.29 | 1.50 | 1.50 | 27.66 | 6.95 | 1.03 | 3.15 | 5.84 | 1,223,535.00 | 5.77 | 0.7814 | 17.83 | 2.35 | 46.14 | 44.03 | 5.62 | 0.8498 | 0.5315 | 6.12 | 0.5393 | 25.76 | 10.58 | 7.88 | 131.99 | 63.55 | 3.86 | 24.57 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.63bn | -344.58m | 20.26bn | 1.45k | -- | 3.38 | -- | 5.58 | -0.2727 | -0.2727 | 2.30 | 3.71 | 0.3561 | 0.4354 | 3.35 | 2,500,466.00 | -3.38 | 8.97 | -4.83 | 13.15 | 43.57 | 45.59 | -9.50 | 20.12 | 1.15 | -- | 0.3129 | 26.33 | 5.89 | 18.25 | -117.37 | -- | 38.32 | 13.75 |
| Tasly Pharmaceutical Group Co Ltd | 8.64bn | 1.10bn | 20.81bn | 9.22k | 18.97 | 1.64 | -- | 2.41 | 0.7342 | 0.7342 | 5.77 | 8.47 | 0.4899 | 1.72 | 10.80 | 937,046.80 | 5.93 | 5.47 | 7.21 | 7.25 | 65.67 | 48.42 | 12.11 | 8.94 | 2.73 | 5.91 | 0.2083 | 50.99 | 0.4236 | -13.57 | 505.34 | -7.07 | -3.03 | 1.92 |
| China Resources Dubl-Crne Phrmctl Co Ltd | 10.32bn | 1.38bn | 22.00bn | 12.27k | 15.77 | 1.88 | -- | 2.13 | 1.34 | 1.34 | 10.07 | 11.24 | 0.6781 | 2.85 | 5.82 | 841,054.60 | 8.87 | 8.58 | 11.67 | 11.21 | 54.25 | 58.19 | 13.08 | 11.98 | 2.15 | -- | 0.0249 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
| Xiamen Amoytop Biotech Co Ltd | 2.23bn | 600.08m | 22.23bn | 1.96k | 37.05 | 11.09 | -- | 9.99 | 1.48 | 1.48 | 5.47 | 4.93 | 1.04 | 0.8541 | 6.70 | 1,135,877.00 | 28.09 | 17.96 | 32.72 | 21.02 | 93.17 | 90.48 | 26.95 | 19.17 | 3.22 | -- | 0.0037 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| Shanghai Junshi Biosciences Co Ltd | 1.63bn | -2.02bn | 23.08bn | 2.57k | -- | 3.85 | -- | 14.18 | -2.06 | -2.06 | 1.66 | 6.97 | 0.1348 | 1.05 | 4.11 | 634,034.10 | -18.18 | -18.87 | -23.17 | -23.11 | 64.05 | 69.13 | -134.86 | -88.41 | 1.91 | -215.80 | 0.3018 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Joincare Pharmaceutical Group Ind. Co. | 16.43bn | 1.42bn | 23.28bn | 14.37k | 16.25 | 1.64 | -- | 1.42 | 0.7676 | 0.7676 | 8.86 | 7.63 | 0.4522 | 2.36 | 5.57 | 1,143,551.00 | 7.98 | 8.46 | 16.51 | 18.84 | 61.23 | 62.72 | 17.64 | 17.00 | 2.11 | -- | 0.2247 | 28.86 | -2.90 | 8.24 | -3.99 | 15.58 | 11.53 | 2.38 |
| Kangmei Pharmaceutical Co Ltd | 4.93bn | 160.40m | 25.65bn | 4.41k | 159.07 | 3.62 | -- | 5.20 | 0.0116 | 0.0116 | 0.3577 | 0.5117 | 0.34 | 1.40 | 2.43 | 1,118,464.00 | 1.12 | -17.60 | 1.69 | -32.24 | 22.71 | -72.78 | 3.28 | -101.19 | 0.8746 | -- | 0.0465 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 8.75bn | 928.37m | 25.71bn | 8.22k | 27.13 | 3.01 | -- | 2.94 | 0.6391 | 0.6391 | 6.02 | 5.76 | 0.4511 | 1.08 | 3.46 | 1,064,162.00 | 4.76 | 5.67 | 6.90 | 8.07 | 59.44 | 60.52 | 10.55 | 11.61 | 0.8451 | 5.48 | 0.5047 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
Data as of May 31 2024. Currency figures normalised to Xiamen Amoytop Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
12.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Yunnan International Trust Co., Ltd.as of 30 Sep 2023 | 11.07m | 2.72% |
| Da Cheng Fund Management Co., Ltd.as of 31 Dec 2023 | 9.05m | 2.23% |
| Tibet Trust Corp. Ltd.as of 30 Sep 2023 | 8.24m | 2.03% |
| GF Securities Asset Management (Guangdong) Co., Ltd.as of 30 Sep 2023 | 5.37m | 1.32% |
| Orient Securities Asset Management Co. Ltd.as of 31 Dec 2023 | 3.32m | 0.82% |
| China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 3.20m | 0.79% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2023 | 2.66m | 0.65% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 2.17m | 0.53% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 2.11m | 0.52% |
| HuaAn Fund Management Co., Ltd.as of 31 Dec 2023 | 1.83m | 0.45% |
More ▼
Data from 30 Jun 2023 - 22 May 2024Source: FactSet Research Systems Inc.
